to my NBER Working Papers:
to my abstracts/papers on the Social Science Research Network:
“The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis.” Forum for Health Economics & Policy, forthcoming.
“How many life-years have new drugs saved? A 3-way fixed-effects analysis of 66 diseases in 27 countries, 2000- 2013,” International Health, forthcoming.
“The impact of access to prescription drugs on disability in eleven European countries.” Disability and Health Journal, available online 23 January 2019.
“The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy following a Major Cardiovascular Event: Evidence from Geisinger,” with Rebecca A. Pulk, Jove Graham, Daniel Maeng, Marc S. Williams, Eric Wright, in Economic Dimensions of Personalized and Precision Medicine, Ernst Berndt, Dana Goldman, and John Rowe, editors, forthcoming.
“The long-run impact of new medical ideas on cancer survival and mortality,” Economics of Innovation and New Technology, Published online: 23 Dec 2018.
"The Physician-Patient Relationship in the Age of Precision Medicine," with Eyal G, Sabatello M, Tabb K, Adams R, Jones M, Nelson A, Ochsner K, Rowe J, Stiles D, Sivaramakrishnan K, Underhill K, Appelbaum PS, Genetics in Medicine, Published: 14 September 2018.
"The impact of new drug launches on longevity growth in 9 Middle Eastern and African countries, 2007-2015," Review of Middle East Economics and Finance, Published Online: 9 September 2018
“The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries,” Journal of Demographic Economics 84: 309–354, Published online: 01 August 2018
“The impact of pharmaceutical innovation on cancer mortality in Russia, 2001-2011,” Journal of Pharmaceutical Health Services Research 9 (2): 79-89, June 2018.
“The Impact of Public and Private Research on Premature Cancer Mortality and Hospitalization in the U.S., 1999- 2013,” The American Economist 63 (2): 147-165, First Published March 26, 2018.
“The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003-2013,” Latin American Economic Review 26:8, December 2017.
“The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia,” Economic Record 93 (302): 353-378, September 2017.
“The impact of biomedical innovation on longevity and health,” Nordic Journal of Health Economics 5 (1): 45-57.
“The impact of pharmaceutical innovation on health outcomes and utilization in Turkey: a re-examination,” with Mehtap Tatar and Zafer Çalışkan, Health Policy and Technology 6(2): 226–233, June 2017.
“The impact of pharmaceutical innovation on cancer mortality in Belgium, 2004-2012,” Forum for Health Economics and Policy 20:1, 2016.
“The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012,” European Journal of Health Economics, 17 (7): 833–854, September 2016.
“The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011,” International Journal of Health Economics and Management 15(3):339-359, June 2015.
“Pharmaceutical innovation, longevity, and medical expenditure in Greece, 1995-2010,” International Journal of the Economics of Business 22(2): 277-299.
“The impact of cardiovascular drug innovation on the longevity of elderly residents of Switzerland, 2003-2012,” Nordic Journal of Health Economics, published online March 2015.
“The Impact of Biomedical Knowledge Accumulation on Mortality: A Bibliometric Analysis of Cancer Data in Measuring and Modeling Health Care Costs,” Ana Aizcorbe, Colin Baker, Ernst Berndt, and David Cutler, editors, forthcoming.
“The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence,” with Gisela Hostenkamp, Social Science & Medicine 130 (2015): 162-171.
“The impact of pharmaceutical innovation on premature mortality, cancer mortality, and hospitalization in Slovenia, 1997-2010,” Applied Health Economics and Health Policy 13(2): 207-22, April 2015.
“The impact of pharmaceutical innovation on disability days and the use of medical services in the United States, 1997-2010,” Journal of Human Capital 8(4): 432-480.
“The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999- 2010,” with Mehtap Tatar and Zafer Çalışkan, Health Policy 117(3): 361-73, September 2014.
“Has Medical Innovation Reduced Cancer Mortality?,” CESifo Economic Studies (2014) 60 (1): 135-177, First published online: November 14, 2013.
“Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009,” Health Policy and Technology 3(1): 36-58, March 2014.
“The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data,” with Billie Pettersson, Economics of Innovation and New Technology 23 (3), 2014: 239-273; Published online: 02 Sep 2013.
“The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009,” Economics and Human Biology 13: 107-127, March 2014.
“The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996–2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files,” Forum for Health Economics and Policy 16(1): 1–33, Published Online 2013-01-24.
“The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000-2007,” Social Science and Medicine 77: 50-9, January 2013.
“The effect of pharmaceutical innovation on the functional limitations of elderly Americans: evidence from the 2004 National Nursing Home Survey,” Advances in Health Economics and Health Services Research 23, 71-99 (2012).
“Is home health care a substitute for hospital care?,” Home Health Care Services Quarterly 31, 8-109 (2012).
“Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization,” with Gautier Duflos, International Review of Law and Economics 32(1), March 2012, 95–109.
“The contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001-2007,” PharmacoEconomics 30(3), March 2012, 197-211.
“The impact of new (orphan) drug approvals on premature mortality from rare diseases in the U.S. and France, 1999-2007, European Journal of Health Economics 14(1): 41-56.
“Has pharmaceutical innovation reduced Social Security Disability growth?,” International Journal of the Economics of Business 18 (2), 2011.
“Pharmaceutical Companies’ Variation of Drug Prices Within and Among Countries Can Improve Social Well Being Over the Long Term,” Health Affairs 30 (8), August 2011; shorter version also published in The World Financial Review, Sept/Oct. 2011.
“What are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation?,” with Bhaven Sampat, Health Affairs 30(2):332-9, Feb. 2011.
“The quality of medical care, behavioral risk factors, and longevity growth,” International Journal of Health Care Finance and Economics 11(1), March 2011, 1-34.
”Spurious correlation in estimation of the health production function: A note,” Economics Bulletin 30 (3), pp. 2505- 2514, September 28, 2010, with Sule Akkoyunlu, Boriss Siliverstovs and Peter Zweifel, http://www.accessecon.com/Pubs/EB/2010/Volume30/EB-10-V30-I3-P230.pdf
"Pharmaceutical Price Discrimination and Social Welfare," Capitalism and Society 5 (1), Article 2, 2010.
"Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia," Forum for Health Economics & Policy 13 (2) (Health Economics), Article 11. http://www.bepress.com/fhep/13/2/11
“The Effect of Patent Expiration on U.S. Drug Prices, Marketing, and Utilization,” with Gautier Duflos, Concurrences (Review of Competition Laws), forthcoming,
“The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program,” in M. Grossman, B. Lindgren, R. Kaestner, and Kristian (eds.), Pharmaceutical Markets and Insurance Worldwide (Advances in Health Economics and Health Services Research, Volume 22), Emerald Group Publishing Limited, pp. 273-292.
“Pharmaceutical Innovation and Mortality in the United States, 1960-2000. A commentary on Schnittker and Karandinos,” Social Science & Medicine 70 (2010), pp. 969-971.
“Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature,” Expert Review of Pharmacoeconomics & Outcomes Research 9 (6), 499-504.
“The impact of drug vintage on patient survival: a patient-level analysis using Quebec’s provincial health plan data,”
with Paul Grootendorst, Marc Van Audenrode, Dominick Latremouille-Viau, and Patrick Lefebvre, Value in Health 12 (6), 847–856.
“International differences in cancer survival rates: the role of new drug launches,” International Journal of Healthcare Technology and Management 10 (3), 2009, 138-55.
“Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act,” with Joel Waldfogel, 15 Michigan Telecommunications and Technology Law Review, 335 (2009), http://www.mttlr.org/volfifteen/lichtenberg&waldfogel.pdf
“The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004,” Economics of Innovation and New Technology 18 (5), 2009, 407-28.
“Home, or nursing home? The effect of medical innovation on the demand for long-term care,” in J. Costa i Font, A. McGuire and C. Courbage (eds), The Economics of New Health Technologies: Incentives, Organisation and Financing, Oxford University Press (2009).
“Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003,” Health Economics 18 (5), 2009, 519-534.
“Pharmaceutical innovation and the longevity of Australians: a first look,” with Gautier Duflos, Advances in Health Economics and Health Services Research 19, 2008, pp 95-117.
"Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data," Forum for Health Economics & Policy: Vol. 10: Iss. 1 (Frontiers in Health Policy Research), Article 1. http://www.bepress.com/fhep/10/1/1
“The Effect Of Education On Medical Technology Adoption: Are The More Educated More Likely To Use New Drugs?,” with Adriana Lleras-Muney, Annales d’Economie et de Statistique 79/80 - Issue special, Juillet - Décembre 2005.
“The impact of Medicare Part D on prescription drug use by the elderly: evidence from a large retail pharmacy chain,” with Shawn Sun, Health Affairs 26(6), November/December 2007, 1735-44; reprinted in the Pharmaceutical Economics volume (ed. by W. S. Comanor and S. O. Schweitzer) of the International Library of Critical Writings in Economics (Edward Elgar Publishing).
“Importation and innovation,” Economics of Innovation and New Technology, 2007, Vol. 16(6), September, pp. 403–417
“Benefits and Costs of Newer Drugs: An Update,” Managerial and Decision Economics 28: 485–490 (2007).
“Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as ‘equipment for your health,’” with Suchin Virabhak, Managerial and Decision Economics 28: 371–392 (2007)
“The Effect of Drug Vintage on Mortality: Economic Effect of New Drugs,” with Kee Taig Jung and Jeong Yoon Kim, Korean Journal of Health Policy and Administration 16(4), December 2006, 147-68.
“Effects of new drugs on overall health spending: Frank Lichtenberg responds,” Health Affairs 26(3), May-June, 887-90.
“The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: state-level evidence from 1997-2003,” Pharmacoeconomics 24 Suppl 3, 2006, 5-25.
“The Impact of New Drugs on U.S. Longevity and Medical Expenditure, 1990-2003,”American Economic Review 97 (2), May 2007, 438-443.
“Ensuring the future supply of vaccines: Is a National Vaccine Authority the answer?,” in Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective , ed. by Chee-Ruey Hsieh and Frank Sloan (Cambridge University Press, 2007), 127-52.
“The impact of increased utilization of HIV drugs on longevity and medical expenditure: an assessment based on aggregate U.S. time-series data,” Expert Review of Pharmacoeconomics and Outcomes Research, Volume 6, Number 4, August 2006, 425-436.
“Did CMS’ Functional Equivalence Decision Result in Equitable Payments?,” Journal of Pharmaceutical Finance, Economics & Policy 15(1), 2006, 7-20.
“Has using newer drugs reduced admissions to hospitals and nursing homes?,” Swiss Journal of Economics and Statistics 142, 2006, pp. 69-75.
“The Benefits to Society of New Drugs: A Survey of the Econometric Evidence,” in Engaging the New World: Responses to the Knowledge Economy, edited by Bhajan S. Grewal and Margarita Kumnick, Melbourne University Press, Melbourne, 2006.
“Pharmaceutical Innovation as a Process of Creative Destruction,” in Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech, ed. by Mariana Mazzucato and Giovanni Dosi (Cambridge University Press, 2006), pp. 21-72.
"Pharmaceutical innovation and the burden of disease in developing countries," Journal of Medicine and Philosophy 30(6), December 2005.
“Pharmaceutical Knowledge-Capital Accumulation and Longevity,” in Measuring Capital in the New Economy, ed. by Carol Corrado, John Haltiwanger, and Dan Sichel, pp. 237-269 (University of Chicago Press, 2005).
"Availability of new drugs and Americans' ability to work," Journal of Occupational and Environmental Medicine 47 (4), April 2005, 373-380.
“The Effect of Access Restrictions on the Vintage of Drugs Used by Medicaid Enrollees,” American Journal of Managed Care 11, Special Issue, 2005, SP7-SP13.
"The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001," International Journal of Health Care Finance and Economics 5, 2005, pp. 47-73.
“Sources of U.S. Longevity Increase, 1960-2001,” Quarterly Review of Economics and Finance 44(3), pp. 369-389 (July 2004).
policy and innovation in the U.S. pharmaceutical industry,"
in Public Policy and Entrepreneurship, ed.
by Douglas Holtz-Eakin (MIT Press, 2004), pp. 83-113.
Dual Effects of Intellectual Property Regulations: Within-
and Between-Patent Competition in The US Pharmaceuticals
Industry," with Tomas Philipson, Journal of Law &
Economics 45, pp. 643-672, 2002.
Effect of New Drugs on HIV Mortality in the U.S., 1987-1998," Economics and Human Biology 1 (2003) 259-266.
Innovation, Mortality Reduction, and Economic Growth," in Measuring the Gains from Medical Research: An Economic Approach, ed.
by Kevin M. Murphy and Robert H. Topel (Chicago: University
of Chicago Press, 2003), pp. 74-109.
Effects of Medicare on Health Care Utilization and Outcomes," Frontiers in Health
Policy Research, Vol. 5, ed. by Alan Garber (MIT Press,
the Benefits of Newer Drugs Worth Their Cost? Evidence from
the 1996 MEPS," Health
Affairs 20(5), September/October 2001, 241-51.
foreign direct investment transfer technology across borders?,"
with Bruno van Pottelsberghe
de la Potterie, The Review of Economics and Statistics,
Aug 2001; Vol. 83, Iss. 3; pp. 490-7.
Allocation of Publicly Funded Biomedical Research," in Medical Care Output and Productivity, Studies
in Income and Wealth Volume 62, ed. by Ernst Berndt and
David Cutler (University of Chicago Press, 2001), 565-89.
Effect of Pharmaceutical Utilisation and Innovation on Hospitalisation
and Mortality," in Productivity,
Technology, and Economic Growth, ed. by B. van Ark,
S. K. Kuipers and G. Kuper (Kluwer Academic Publishers,
European Strategic Programme for Research in Information
Technologies (ESPRIT): An Ex-Post Analysis," in The
Political Economy of Industrial Policy, ed. by D. Neven
and Lars-Hendrik Roller (Wissenschaftszentrum Berlin and
"Managerial Ownership and Firm Performance: A Re-examination
Using Productivity Measurement," with Darius Palia, Journal of Corporate Finance: Contracting,
Governance and Organization 5(4), December 1999, 323-39.
"Information Technology and Its Impact on Productivity:
Firm-level Evidence from Government and Private Data Sources,
1977-1993," with Bill Lehr, Canadian
Journal of Economics 32(2), April 1999, 335-62.
Use and Productivity Growth in Federal Government Agencies,
1987-92," with Bill Lehr, Journal
of Industrial Economics 46(2), June 1998, 257-79.
R&D Spillovers: A Comment," with Bruno van Pottelsberghe
de la Potterie, European Economic Review 42(8), September
Impact and Organization of Publicly-Funded Research and
Development in the European Community," with Maryann Feldman, Annales d'Economie
et Statistique 0(49-50), (in English), Jan.-June 1998,
Investment is Driving Economic Growth," in
The Rising Tide, ed. by Jerry Jasinowski (New York:
Wiley, 1998), 163-9.
Shoring up Government Support," in The
Future of Biomedical Research, ed. by Claude Barfield
and Bruce Smith (Washington: American Enterprise Institute
and Brookings Institution, 1997), 67-72.
(More and Better) Drugs Keep People Out of Hospitals?," American Economic Review 86, May, 1996, 384-8.
Market Institutions, Liquidity Constraints, and Macroeconomic
Stability," Journal of Economic Behavior and Organization 28 (1995), 145-54.
Output Contributions of Computer Equipment and Personnel:
A Firm-Level Analysis," Economics
of Innovation and New Technology 3 (1995), 201-17.
Economics of Defense R&D," in The
Handbook of Defense Economics, Volume 1, ed. by K. Hartley
and T. Sandler. Handbooks in Economics, vol. 12. (Amsterdam,
New York and Oxford: Elsevier, 1995), 431-57.
Structure and Corporate Performance in Japan," with
George Pushner, Japan and the World Economy 6 (1994), 239-61.
the Convergence Hypothesis," Review
of Economics and Statistics 76(3), August 1994, 576-9.
Industry-Level Analysis of Import Relief Petitions Filed
by U.S. Manufacturers, 1958-1985," with Hong Tan, in Troubled Industries
in the United States and Japan, ed. by Hong Tan and
Haruo Shimada (New York: St. Martin's Press, 1994), 161-88.
International Differences in Educational Attainment Levels
Narrowed?," in Convergence of Productivity: Cross-National
Studies and Historical Evidence, ed. by W. Baumol, R.
Nelson, and E. Wolff (New York: Oxford University Press,
Investment and International Productivity Differences,"
in Economic Growth in the World Economy, ed.
by Horst Siebert (Tubingen: J. C. B. Mohr, 1993), 89-110.
De-Diversification and Its Consequences for Productivity," Journal of Economic Behavior and Organization 18 (1992), 427-38.
Perspective on Accounting for Defense Contracts," The Accounting Review 67 (4), 742-53, October 1992.
Stripping," in The
New Palgrave Dictionary of Money and Finance, J. Eatwell,
M. Milgate, and P. Newman, eds. (London: Macmillan, 1992).
Managerial Response to Regulation of Financial Reporting
for Segments of a Business Enterprise," Journal
of Regulatory Economics 3 (1991), 241-9.
Age of Technology and Its Impact on Employee Wages,"
with Ann Bartel, Economics of Innovation and New Technology 1 (1991), 215-31.
Impact of R&D Investment on Productivity: New Evidence
Using Linked R&D-LRD Data," with Donald Siegel, Economic Inquiry 29 (1991), April, 203-28.
Effect of Leveraged Buyouts on Productivity and Related
Aspects of Firm Behavior," with Donald Siegel, Journal
of Financial Economics 26 (1990), 165-94.
Effect of Ownership Changes on the Employment and Wages
of Central-Office and Other Personnel," with Donald
Siegel, Journal of
Law and Economics 33 (1990), October, 383-408.
Government Subsidies to Private Military R&D: The Defense
Department's Independent R&D Policy," Defense
Economics 1 (1990), 149-58.
of Variables in Least-Squares Regression," American Statistician 44 (1990), 169-71.
in Measuring Industrial R&D," Research
Policy 19 (1990), 157-63.
Elastic is the Government's Demand for Weapons?," Journal of Public Economics 40 (1989), 57-78.
Effect of Control Changes on the Productivity of U.S. Manufacturing
Plants," with Donald Siegel, Journal
of Applied Corporate Finance, August 1989, 60-7.
to Federal Election Campaigns by Government Contractors," Journal of Industrial Economics 38, September
Project Data and Theories of R&D Investment," Journal of Economic Dynamics and Control 13, 1989, 271-82.
of Measurement in Output Deflators," with Zvi Griliches, Journal of Business and Economic Statistics 7, Jan. 1989, 1-9.
Impact of the Strategic Defense Initiative on U.S. Civilian
R&D Investment and International Competitiveness," Social Studies of
Science 19(2), 1989; also published (in French) in J.J.
Salomon (ed.), Science,
Guerre et Paix (Paris: Economica, 1989), 137-56.
Economics," in The
Portable MBA, Mary Anne Devanna and Eliza G.C. Collins,
eds. (New York: Wiley, 1989).
of the Internal Adjustment Costs Model Using Longitudinal
Establishment Data," Review
of Economics and Statistics 70(3), August 1988, 421-30.
Private R&D Investment Response to Federal Design and
Technical Competitions," American
Economic Review 78(3), June 1988, 550-9.
Improvements from Changes in Ownership," Mergers and Acquisitions 23(2), Sept./Oct. 1988, 48-50.
the Impact of Federal Industrial R&D Expenditure on
Private R&D Activity in the U.S.," in The
Relation Between Defence and Civil Technologies, Philip
Gummett and Judith Reppy, eds. (Dordrecht: Kluwer Academic
Publishers, 1988), 68-87.
and Changes in Ownership of Manufacturing Plants,"
with Donald Siegel, Brookings Papers on Economic Activity,
Effect of Government Funding on Private Industrial Research
and Development: A Re-Assessment," Journal
of Industrial Economics 36(1), Sept. 1987.
Market Opportunities and the Structure of R&D Investment:
The Case of Energy," Energy
Economics 9(3), July 1987, 154-8.
Comparative Advantage of Educated Workers in Implementing
New Technology," with Ann Bartel, Review
of Economics and Statistics 69(1), Feb. 1987, 1-11.
Skill Distribution and Competitive Trade Advantage of High-Technology
Industries," with Ann Bartel, in Advances
in Industrial and Labor Relations, Vol. 4, D. Lewin,
D. Lipsky, and D. Sockell, eds. (JAI Press, 1987).
Duration and Intensity of Investment in Independent Research
and Development Projects," Journal
of Economic and Social Measurement 14, 1986, 207-18.
Prices and Induced Innovation," Research
Policy 15, 1986, 67-75.
Technology Flows and Productivity Growth: A Re-Examination,"
with Zvi Griliches, Review
of Economics and Statistics 66(2), May 1984.
Relationship Between Federal Contract R&D and Company
R&D," American Economic Association Papers and Proceedings 74(2), May 1984.
and Productivity at the Industry Level: Is There Still a
Relationship?," with Zvi Griliches, in R&D, Patents, and Productivity, Zvi Griliches, ed. (Chicago: Univ.
of Chicago Press, 1984).
the Link Between Gross Profitability and R&D Spending," Health Affairs 20(5), September/October 2001, 221-2.
on Papers by Frank and Salkever and by Skinner and Wennberg,
in The Changing Hospital Industry: Comparing Not-for-Profit
and For-Profit Institutions, edited by David M. Cutler,
The University of Chicago Press, 2000.
on Paper by Barro and Cutler, in Mergers
and Productivity, edited by Steven N. Kaplan, The University
of Chicago Press, 2000.
on Paper by McGuckin, Nguyen, and Reznek, in Labor
Statistics Measurement Issues edited by John Haltiwanger,
Marilyn E. Manser, and Robert Topel, The University of Chicago
(more and better) medicines keep people out of hospitals?"
(Pfizer Forum), The Economist, October 26, 1996, p. 63.
of The Performance
of Companies, by Stephen Nickell (Oxford, U.K.: Blackwell,
1995), in The Journal
on "Efficiency in manufacturing and the need for global
competition," by Martin Baily and Neil Gersbach, Brookings Papers on Economic Activity: Microeconomics 1995.
to Comment by Maarten Vendrik," Journal of Economic Behavior and Organization 28,
Dec. 1995, p. 455.
on " Productivity levels in Germany, Japan, and the
United States: Differences and causes," by Bart van
Ark and Dirk Pilat, Brookings Papers on Economic Activity: Microeconomics 1993.
Way to Measure IT's Productivity Contribution," The Brookings Review 12, Fall 1994, 2.
of International High-Technology Competition,
by F. M. Scherer, in
The Journal of Economic Literature XXXI (4), Dec. 1993,
on "Decade of Debt: Lessons from LBOs in the 1980s,"
by William Long and David Ravenscraft, in The
Deal Decade: What Takeovers and Leveraged Buyouts Mean for
Corporate Governance, edited by Margaret Blair (Washington:
Brookings, 1993), 230-234.
a Downturn, Cut Profits Before Jobs" New
York Times (Sunday Business Section), Feb. 16, 1992,
Section 3, p. 13.
More Productivity? Kill That Conglomerate," Wall
Street Journal (editorial page article), Jan. 16, 1990.
Issues in Restructuring," Institutional
Investor, June 1989.
Takeover Wars, Everyone Wins," New York Times (Business Forum article),
June 18, 1989.
Slash Corporate Overhead," Wall
Street Journal (editorial page article), Feb. 7, 1989.
Makes Plant Productivity Grow?," Wall
Street Journal (editorial page article), Dec. 24, 1987;
also published (in Italian) in Il
Sole 24 Ore (Milan), Jan. 20, 1988.
of The Burden of Government, by Edwin S. Mills
(Stanford: Hoover Institution Press, 1986) in Journal of Comparative Economics 12(2), June 1988, 304-5.
R&D Depletes Economic Might," Wall
Street Journal (editorial page article), Aug. 21, 1986;
reprinted in Impact, newsletter of the Institute of
Electrical and Electronic Engineers 11(1), May 1987.
"Sources of U.S. Longevity Increase, 1960-1997,"
NBER Working Paper No. 8755, Jan 2002.
"Benefits and Costs of Newer Drugs: An Update,"
NBER Working Paper No. 8996, Jun 2002.
Effect of Education on Medical Technology Adoption: Are
the More Educated More Likely to Use New Drugs?," with Adriana
Lleras-Muney, NBER Working Paper No. 9185, Sep 2002.
"The Effect of Changes in Drug Utilization on
Labor Supply and Per Capita Output," NBER Working Paper
No. 9139, Sep 2002.
"Pharmaceutical-embodied technical progress,
longevity, and quality of life: drugs as 'equipment for
your health'," with S. Virabhak, NBER Working
Paper No. 9351, Nov 2002.
Misery Love Company? Pharmaceutical Markets before and after the
Orphan Drug Laws," with Joel Waldfogel, Jan. 2002.